- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01670981
An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM) (ixCELLDCM)
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of Transendocardial Injection of Ixmyelocel-T in Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 287
- University of Alberta Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 1C8
- Montreal Heart Institute
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
Birmingham, Alabama, United States, 35211
- Cardiology, P.C. & Center for Therapeutic Angiogenesis
-
-
Arizona
-
Gilbert, Arizona, United States, 85297
- Mercy Gilbert Medical Center
-
Phoenix, Arizona, United States, 85054
- Mayo Clinic Arizona
-
-
California
-
La Jolla, California, United States, 92037
- Scripps Clinic
-
La Jolla, California, United States, 92037
- UCSD Medical Center
-
Los Angeles, California, United States, 90095
- University of California Los Angeles (UCLA)
-
Los Angeles, California, United States, 90048
- Cedars-Sinai Heart and Lung Institute
-
Oxnard, California, United States, 93030
- St. John's Regional Medical Center
-
Stanford, California, United States, 94305
- Stanford University
-
-
Florida
-
Daytona Beach, Florida, United States, 32117
- Cardiology Research Associates
-
Gainesville, Florida, United States, 32610
- University of Florida - Division of Cardiology
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic Florida (Jacksonville)
-
Miami, Florida, United States, 33136
- University of Miami - Miller School of Medicine
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University Hospital
-
Augusta, Georgia, United States, 30912
- Georgia Regents University
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Clinic Foundation
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital, Division of Cardiology
-
-
Michigan
-
Saginaw, Michigan, United States, 48602
- Michigan CardioVascular Institute
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
New Jersey
-
Newark, New Jersey, United States, 07112
- Newark Beth Israel Hospital
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- The Carl and Edyth Linder Center for Research & Education at The Christ Hospital
-
Cleveland, Ohio, United States, 44106
- University Hospitals - Case Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19140
- Temple University
-
Pittsburgh, Pennsylvania, United States, 15213
- UPMC Cardiovascular Institute
-
Pittsburgh, Pennsylvania, United States, 15240
- Veterans Administration Healthcare System
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- Stern Cardiovascular Foundation, Inc.
-
-
Texas
-
Dallas, Texas, United States, 75226
- Soltero Cardiovascular Research Center
-
Houston, Texas, United States, 77030
- Methodist DeBakey Heart and Vascular Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah Health Services Center
-
-
Washington
-
Seattle, Washington, United States, 98122
- Swedish Medical Center - Cherry Hill Professional Building
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin-Madison Cardiovascular Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and non-pregnant, non-lactating females;
- Age 30 to 86 years of age;
- Diagnosis of ischemic dilated cardiomyopathy;
- LVEF ≤ 35% by echocardiogram;
- Symptomatic heart failure in NYHA functional class III or IV;
- Subject is not a candidate for reasonable revascularization procedures that will produce clinical improvement;
- Subject is receiving appropriate clinical standard of care heart failure therapy, as tolerated and as dictated by a subject's current medical condition, for at least 30 days prior to screening;
- Must have an automatic implantable cardioverter defibrillator (AICD);
- Worsening heart failure hospitalization or equivalent within 6 months prior to screening, hospitalization equivalent defined as an unplanned outpatient/emergency department visit for treatment of acute decompensated heart failure; or have an N-terminal prohormone B-type natriuretic peptide (NT-proBNP) ≥2000 pg/mL or BNP ≥400 pg/mL within 30 days of screening (including screening); or have a 6-minute walk test (6MWT) distance of ≤400 meters at screening;
- Life expectancy of at least 12 months in the opinion of the Investigator;
- LV wall thickness ≥ 7mm (by echocardiogram) at anticipated target injection area;
- Hemodynamic stability without IV vasopressors or support devices;
- Given medical history and concurrent medication, subject is an acceptable candidate for bone marrow aspiration and cardiac catheterization and transendocardial injection procedures in the opinion of the Investigator;
- Willing and able to comply scheduled visits and tolerate study procedures.
- Voluntarily provide a personally-signed and dated informed consent.
Exclusion Criteria:
Disease-specific:
- Severe primary valvular heart disease including, but not limited to, aortic valve stenosis and insufficiency;
- VAD implantation, heart transplantation, cardiomyoplasty, left ventricular reduction surgery, or cardiac shunt implantation;
- Planned heart failure-related device interventions (e.g., VAD implantation, initial cardiac resynchronization therapy) or planned cardiac procedures (e.g., heart transplant, cardiomyoplasty, valvular repair);
- Current arrhythmias that would prohibit accurate NOGA® electromechanical mapping and NOGA®-guided injections;
- LV thrombus (as documented on echocardiography or LV angiography);
- Myocardial infarction, stroke or transient ischemic attack within 3 months prior to screening;
- Percutaneous coronary intervention, valvuloplasty, cardiac surgery, and other major cardiac procedure within 30 days prior to screening;
In the opinion of the Investigator, the subject's left ventricular wall is unsuitable for transendocardial injections (due to thickness or other reasons).
Medical History:
- Stroke or transient ischemic attack (TIA) within 3 months of screening;
- Hemoglobin A1c (HbA1c) ≥ 9% at screening;
- Diabetic subjects with uncontrolled or untreated proliferative retinopathy as determined by dilated eye exam administered by a qualified eye care professional as per American Diabetes Association guidelines;
- Blood clotting disorder not caused by medication (e.g., thrombophilia);
- Active malignancy (non-basal cell) requiring surgery, chemotherapy, and/or radiation in the past 12 months;
- Drug or alcohol abuse that would interfere with the subject's compliance with study procedures;
- Allergies to any equine, porcine, or bovine products;
- Body mass index (BMI) ≥ 40 kg/m2 at screening;
- Established chronic kidney disease (CKD) requiring dialysis (Stage 5); estimated creatinine clearance < 15 mL/min at screening;
Subject has allergy or is unable to tolerate cardiac imaging contrast agents; also the inability to get a good quality echocardiogram image at screening (as determined by the imaging core lab).
Laboratory Parameters:
Abnormal laboratory values (performed at central lab) at screening:
- Platelets < 50,000 μL;
- Hemoglobin < 9.0 g/dL;
- Aspartate aminotransferase/alanine aminotransferase (AST/ALT) > 3 times the upper limit of normal (ULN);
- Human immunodeficiency virus 1 (HIV 1), HIV 2, or syphilis positive (rapid plasma reagin [RPR]);
- Active hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies;
- NOTE: Additional lab tests may be performed per local requirements including but not limited to: hepatitis B core antibody, human T lymphotropic virus I/II.
Exclusionary Procedures, Devices, or Medication:
- Subjects receiving anti-angiogenic drugs (e.g., anti-vascular endothelial growth factor [VEGF]);
- Chronic exposure to cytotoxic therapy for oncologic or chronic non-oncologic reasons in the prior 3 months or expected requirement over the course of the study;
- Concurrent participation in another interventional clinical trial or receiving experimental intervention within 30 days of screening or having previously been exposed to Aastrom's ixmyelocel T product or previously received allogeneic cell therapy, autologous cell therapy cultured with animal proteins.
- In the opinion of the Investigator, the subject is unsuitable for cellular therapy or has a food/drug allergy, surgical or medical condition, clinically significant psychiatric disorders, poor nutritional status, or lab abnormality requiring further medical evaluation that may interfere with the investigational product, interfere with the study results' interpretation, interfere with the subject's ability to complete the study or compromise the subject's safety.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ixmyelocel-T
Ixmyelocel-T delivered by catheter-based intramyocardial injection procedure.
|
12-20 transendocardial injections of 0.4 mL of ixmyelocel-T per injection into the left ventricle.
|
PLACEBO_COMPARATOR: Placebo
Placebo delivered by catheter-based intramyocardial injection procedure.
|
12-20 transendocardial injections of 0.4 mL of vehicle control per injection into the left ventricle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average number of clinical events over 12 months post-treatment.
Time Frame: 12 Months
|
The primary endpoint will assess the efficacy of ixmyelocel-T compared to placebo (vehicle control) on the average number of events per patient over 12 months post-treatment in each treatment arm (total number events in each arm/total number of patients in each arm).
The events include: all-cause deaths, cardiovascular hospitalizations, and unplanned outpatient or emergency department visits to treat acute decompensated heart failure.
The clinical events used in this endpoint will be adjudicated by an independent clinical endpoint committee who are blinded to treatment.
|
12 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The win ratio of the hierarchical occurrence of all-cause deaths/left ventricular assist device (LVAD) implant/heart transplant, cardiovascular hospitalizations, and unplanned outpatient and ED interventions to treat ADHF
Time Frame: 12 Months
|
This is a composite end point.
This endpoint will be primarily assessed excluding events considered to be related to administration of IP.
An analysis including IP administration-related events will also be conducted as part of the sensitivity analyses.
|
12 Months
|
Change from baseline to 12 months post-treatment in 6-minute walk test.
Time Frame: 12 Months
|
A secondary objective will be to evaluate the changes from baseline to 12 months post-treatment in the distance walked as measured by the 6-minute walk test.
|
12 Months
|
Change from baseline to 12 months post-treatment in left ventricular function as evaluated by echocardiography.
Time Frame: 12 Months
|
A secondary objective will be to evaluate the change in left ventricular function as measured by echocardiography for left ventricular ejection fraction (LVEF).
|
12 Months
|
Change from baseline to 12 months post-treatment in quality of life.
Time Frame: 12 Months
|
A secondary objective will be to evaluate the change in quality of life (total score) in patients treated with ixmyelocel-T compared to placebo using the Minnesota Living with Heart Failure Questionnaire.
|
12 Months
|
Change from baseline to 12 months post-treatment in NYHA Classification.
Time Frame: 12 Months
|
A secondary objective will be to evaluate the change from baseline to Month 12 in NYHA Classification in patients treated with ixmyelocel-T compared to placebo.
|
12 Months
|
Percent of patients with adverse events.
Time Frame: 12 Months
|
A secondary objective will be to evaluate the overall safety and tolerability of ixmyelocel-T versus placebo in patients with DCM from time of aspiration through 12 months post-treatment/follow-up by % of patients with adverse events.
|
12 Months
|
Percent of patients with major adverse cardiac events (MACE).
Time Frame: 12 Months
|
A secondary objective will be to evaluate the overall safety and tolerability of ixmyelocel-T versus placebo in patients with DCM by the percentage of patients who experience MACE events.
MACE events include: unstable angina requiring hospitalization, myocardial infarction, stroke, worsening heart failure requiring hospitalization, VAD implantation, heart transplant, resuscitated sudden death, and cardiovascular death.
|
12 Months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABI 55-1202-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Dilated Cardiomyopathy (IDCM)
-
National University of MalaysiaCytopeutics Sdn. Bhd.UnknownIschemic Dilated CardiomyopathyMalaysia
-
The Research-Clinical Center for Cardiac Surgery...State-Financed Health Facility "Samara Regional Medical Center Dinasty"CompletedChronic Heart Failure | Non-ischemic Cardiomyopathy | Non-ischemic Dilated CardiomyopathyKazakhstan
-
University of Cape TownMedtronicSuspendedDilated Cardiomyopathy | Ischemic Cardiomyopathy | Non-ischemic CardiomyopathySouth Africa
-
Capricor Inc.National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaboratorsUnknownHeart Failure | Ischemic Cardiomyopathy | Nonischemic Cardiomyopathy | Dilated Cardiomyopathy (DCM)United States
-
IRCCS SYNLAB SDNCompletedPatients With Ischemic or Idiopathic Dilated CardiomyopathyItaly
-
Joshua M HareNational Heart, Lung, and Blood Institute (NHLBI)CompletedNon-ischemic Dilated CardiomyopathyUnited States
-
Prof. Dr. med. Ingo EitelDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)RecruitingNon-ischemic Dilated CardiomyopathyGermany
-
JKastrupUniversity Medical Centre LjubljanaUnknownNon-ischemic Dilated CardiomyopathyDenmark
-
Joshua M HareThe University of Texas Health Science Center, Houston; United States Department...RecruitingNon-ischemic Dilated CardiomyopathyUnited States
-
Consorcio Centro de Investigación Biomédica en...Instituto de Salud Carlos IIIRecruitingNon-ischemic Dilated CardiomyopathySpain
Clinical Trials on ixmyelocel-T
-
Vericel CorporationCompletedPeripheral Arterial DiseaseUnited States
-
Vericel CorporationCompletedDilated CardiomyopathyUnited States
-
Vericel CorporationCompletedDilated CardiomyopathyUnited States
-
Vericel CorporationCompletedOsteonecrosisUnited States
-
Vericel CorporationCompletedCritical Limb IschemiaUnited States
-
University of MichiganCompleted
-
University of MichiganVericel CorporationCompletedAlveolar Bone LossUnited States
-
Biotronik SE & Co. KGCompletedHeart Failure | BradycardiaDenmark, Hong Kong, Austria, Germany, Belgium
-
University of California, BerkeleyUniversity of Nevada, Reno; World Bank; L'Office National de Nutrition, MadagascarRecruitingEarly Childhood DevelopmentMadagascar
-
Biotronik SE & Co. KGCompletedVentricular Fibrillation | Ventricular TachycardiaGermany, Czech Republic